HOME >> BIOLOGY >> NEWS
The Origin, Evolution, and Future of Life on Earth

A roundtable discussion
Thursday, December 8, 2005 at 7:30pm
in the Philoctetes Center and Auditorium of The New York Psychoanalytic Institute
247 East 82nd Street, New York, NY 10028

How did life begin? What were its earliest forms? Where did it originate? Was it chance or inevitable? Is a biochemical understanding sufficient to explain creation? How did early molecules evolve into today's humans? What can be said about the development of the mind? What of the phenomenon of consciousness? Can culture, civilization, and technology influence evolution in the future, or will Darwinian rules alone prevail? What dangers lie ahead?

These and other like questions will be examined in this roundtable whose participants come from a wide variety of disciplines: biochemistry, paleontology, philosophy, science and religion. Five prominent scholars discuss these important questions about the past and the future of life on earth.

Participants:

Christian de Duve, 1974 Nobel Prize winner in medicine; author of Singularities (Publication date: September 2005

Colin McGinn, Philosopher (consciousness, intentionality, imagination), author, The Character of Mind; Problems in Philosophy: The Limits of Inquiry

Mark Norell, Curator & Chairman of Paleontology, American Museum of Natural History

Robert Pollack, Professor of Biological Sciences and Director of Columbia University's Center for the Study of Science and Religion

James P. Ferris, Director, New York Center for Studies of the Origin of Life, Rensselaer Polytechnic Institute

This program will take place in the Philoctetes Center, and broadcast through closed circuit television to additional seating in the Auditorium. The event is free and open to the public. Seating is limited on a first come basis.


'"/>

Contact: Ellen Fertig
efertig@nyc.rr.com
212-861-8718
Philoctetes Center for the Multidisciplinary Study of Imagination
17-Nov-2005


Page: 1

Related biology news :

1. Arizona State University hosts Genomes, Evolution, and Bioinformatics conference
2. On life support: Future of science focus of lecture at UH
3. Keck Futures Initiative announces grant recipients
4. The Future of Chemical Plant Security one-day symposium, Monday, Aug. 29
5. National Academies Keck Futures Initiative to co-sponsor life engineering symposium
6. Future diabetes drugs may target new protein interaction
7. Future Vision 2005 to feature innovation in endoscopy
8. What we can learn from the biggest extinction in the history of Earth
9. Chickens also orient themselves by the Earths magnetic field
10. Scientists ponder plant life on extrasolar Earthlike planets
11. NASA-funded robotic sub makes final dive to reach bottom of Earths deepest sinkhole

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Origin Evolution and Future Life Earth

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: